Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition. - Lyrarakis G; Liontos M; Anastasopoulou A; Bouros S; Gkoufa A; Diamantopoulos P; Gogas H; Ziogas DC (Frontiers in oncology, 2024)